NGM Stock Alert

Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) to affiliates of The Column Group, LP for $1.55 in cash per share is fair to NGM shareholders.

Halper Sadeh encourages NGM shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether NGM and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for NGM shareholders; (2) determine whether Column Group is underpaying for NGM; and (3) disclose all material information necessary for NGM shareholders to adequately assess and value the merger consideration.

On behalf of NGM shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226906392/en/

The NGM Biopharmaceuticals Stock at the time of publication of the news with a fall of -19,63 % to 1,535USD on Nasdaq stock exchange (26. Februar 2024, 17:20 Uhr).